PDF factsheet
      Z

myocardial revascularization in acute myocardial infarction for facilated PCI, clinical trials results

Abciximab versus primary intervention
ERAMI (Mesquita Gabriel), 2003
facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion
versus
primary intervention
symptom duration <12h
Follow-up duration: 30-day
FINESSE (abciximab-facilitated PCI), 2008
NCT00046228
abciximab-facilitated PCI
versus
primary PCI (abciximab administered immediately before the procedure)
patients with acute ST-segment elevation myocardial infarction; symptom duration <6h open
Follow-up duration: 90 days
REOMOBILE (Arntz), 2003
facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
Zorman, 2002
facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion
versus
primary intervention
symptom duration <12h
Follow-up duration: In hospital
ReoPro-BRIDGING (Gyongyosi), 2004
facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
Bellandi, 2006
facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
Abciximab + reteplase versus primary intervention
BRAVE (Kastrati), 2004
facilated PCI with Abciximab, 0·25 mg/kg intravenouse bolus, 0·125 µg/kg per min infusion and reteplase 5 units (intravenous double bolus)
versus
symptom duration <12h
Follow-up duration: 30 days
FINESSE (combination-facilitated PCI), 2008
NCT00046228
combination-facilitated PCI with abciximab plus half-dose reteplase
versus
primary PCI (abciximab administered immediately before the procedure)
patients with acute ST-segment elevation myocardial infarction; symptom duration <6hopen
Follow-up duration: 90 days
alteplase versus primary intervention
LIMI (Vermeer), 1999
facilated PCI with Alteplase 50 mg(intravenous bolus)mag
versus
primary intervention
symptom duration <6h
Follow-up duration: 42-day
PACT (Ross,), 1999
facilated PCI with alteplase 50 mg (intravenous bolus)
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
Eptifibatide versus primary intervention
INTAMI (Zeymer), 2005
facilated PCI with Eptifibatide; 180 µg/kg intravenous double bolus, 2·0 µg/kg per min infusion
versus
primary intervention
symptom duration <12h
Follow-up duration: 30-day
Eptifibatide + tenecteplase versus primary intervention
ADVANCE-MI, 2005
facilated PCI with Eptifibatide, 180 µg/kg intravenous double bolus, 2·0 µg/kg per min infusion and tenecteplase 0·25 mg/kg (intravenous bolus)
versus
symptom duration <4h
Follow-up duration: 30 days
streptokinase versus primary intervention
SAMI (O’Neill), 1992
facilated PCI with streptokinase 1·5 million units(intravenous)
versus
primary intervention
symptom duration <4h
Follow-up duration: In hospital
PRAGUE (Widimisky), 2000
facilated PCI with Streptokinase 1·5 million units (intravenous)
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
tenecteplase versus primary intervention
GRACIA (Fernandez-Aviles,), 2004
facilated PCI with bodyweight-adjusted intravenous tenecteplase bolus: 30 mg of drug if bodyweight <60 kg, 35 mg if60–69 kg, 40 mg if 70–79 kg, 45 mg if 80–89 kg, and 50 mg if >=90 kg and Abciximab; 0·25 mg/kg intravenousbolus, 0·125 g/kg per min infusi
versus
primary intervention
symptom duration <12h
Follow-up duration: 30-day
Tirofiban versus primary intervention
On-Time (van’t Hof), 2004
facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion
versus
primary intervention
symptom duration <6h
Follow-up duration: 30-day
TIGER-PA (Lee), 2003
facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion
versus
primary intervention
symptom duration <12h
Follow-up duration: 30-day
Cutlip, 2003
facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion
versus
primary intervention
symptom duration <12h
Follow-up duration: 30-day

  Options


in first

in second

  Filter